Global Peptide Therapeutics Market

Biosimilar therapeutic peptides refer to a peptide drug that is used in place of or in addition to peptide hormones when endogenous levels tend to decline. Therapeutic peptides that are biosimilar have applications in the treatment of cancer, metabolic, pulmonary, cardiovascular, and other illnesses. The two main types of biosimilar therapeutic peptides are innovative and generic. Biosimilar medications are frequently mistaken for generic drugs. Both are marketed as low-cost knockoffs of high-priced name-brand medications. The main distinction is that generics are duplicates of synthetic pharmaceuticals, whereas biosimilars are based on drugs that contain biological organisms as active components. The different routes of administration include the parenteral route, the transdermal route, and others and are used in cancer, cardiovascular disorders, central nervous system, metabolic disorders, infections, haematological disorders, gastrointestinal disorders, dermatology, and respiratory disorders. The biosimilar therapeutic peptides market research report is one of a series of new reports from The Business Research Company that provides biosimilar therapeutic peptides market statistics, including global market size, regional shares, competitors with a biosimilar therapeutic peptides market share, detailed biosimilar therapeutic peptides market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilar therapeutic peptides industry. This biosimilar therapeutic peptide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilar therapeutic peptides market grew from $1.21 billion in 2022 to $1.58 billion in 2023 at a compound annual growth rate (CAGR) of 30.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar therapeutic peptides market is expected to grow from $3.9 billion in 2027 at a CAGR of 25.3%. The increasing ageing population is projected to surge the number of patients with chronic diseases, contributing to the biosimilar therapeutic peptides’ market's growth. Elderly people are more prone to various chronic diseases, which are surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world’s population over the age of 60 is expected to reach 2 billion by the end of 2050. Moreover, according to the World Population Prospects, the number of people aged 80 and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancers. The expected increase in the ageing population suffering from various chronic conditions will drive the biosimilar market. The long and costly drug approval process is expected to limit the growth of the biosimilar therapeutic peptide market over the upcoming years. The development, approval, and launch of new drugs is an expensive and prolonged procedure that includes expensive research stages. A new drug has to go through four phases of clinical trials and screening by the regulatory body, including the Food and Drug Administration (FDA) (USA), the Medicines and Healthcare Products Regulatory Agency (MHRA) (UK), and the Medicines and Healthcare Products Regulatory Agency (MHRA) (India). For instance, in September 2020, according to an article shared by Proclinical, a UK-based recruitment agency in the life sciences sector, the average cost to create a new drug is close to $4 billion, however, this cost might occasionally reach $10 billion. No other sector invests more in R&D than the semiconductor industry. According to a recent research, R&D costs are predicted to climb by 3% annually and surpass $203 billion by 2024, therefore, this trend is only projected to continue. Therefore, a long and costly drug approval process is anticipated to hinder the growth of the biosimilar therapeutic peptide market. During the forecast period, the biosimilar therapeutic peptides market is expected to witness growth in research collaborations as well as research funding approvals. Collaborations with other companies and organisations are being prioritised by key companies in order to improve research and development, expand product portfolios, and expand geographical reach.For instance, in January 2020, a UK-based biotechnology company focusing on developing a class of therapeutics based on its proprietary bicyclic peptide technology announced a collaboration with Cancer Research UK to develop BT7401, a new bicyclic immuno-oncology candidate. Cancer Research UK will fund and sponsor the development of a new candidate. In addition to this, Sapience Therapeutics, Inc., a US-based biotechnology company focused on the research & development of peptide therapeutics, announced a research collaboration with the University of Bath (UK) to develop and discover new therapeutic agents for oncology applications. Hence, research collaborations to develop new therapeutic peptides are a major trend in the market. In September 2020, Ligand Pharmaceuticals Incorporated, a US-based biopharmaceutical company, acquired Pfenex Inc. for an undisclosed amount. The acquisition would provide Ligand access to its proprietary protein expression technology. The transaction has the potential to have a materially beneficial scientific and financial impact on our business in the immediate and long terms. Pfenex would provide Ligand with a well-established, tested protein expression platform that would provide a great complement to our vital, exclusive drug discovery and formulation technologies. Pfenex Inc. is a US-based manufacturer of biosimilars, including teriparatide, ranibizumab, and pegfilgrastim. Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC., GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. North America was the largest region in the biosimilar therapeutics market in 2022. The Middle East is expected to be the fastest growing region in the global biosimilar therapeutic peptides market during the forecast period. The regions covered in the global biosimilar therapeutic peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilar therapeutic peptides market consists of sales of pegfilgrastim, bevacizumab, and adalimumab. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar therapeutic peptides market is segmented - 1) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations 2) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders 3) By Type: Innovative, Generic

The nutraceuticals are classified as food but are also used for medical purposes. Nutraceuticals are specially designed consumable products from various food sources that contain a high concentration of bioactive compounds that have several nutritional, health, and medicinal benefits. Nutraceutical products and supplements can be taken by an individual along with a normal daily diet to get additional nutrients to promote good health and wellbeing. Nutraceutical products are used to improve health, prevent chronic diseases, increase life expectancy, and support the physical and mental health of an individual. They are also proven to have a potentially positive effect on health conditions like cardiovascular disease, hypertension, diabetes, inflammation, cancer, and others. The main types of nutraceuticals are vitamins and minerals; probiotics; proteins and peptides; omega fatty acids; and others. Vitamins and minerals are nutrients required for the body's daily functioning. Vitamins and minerals are added into food products to increase the nutritional value of food to improve the health of an individual and provide them with high immunity. These are classified according to their source, which can be plant, animal, or microbial. These nutraceutical products are used in various applications, such as functional food, functional beverages, dietary supplements, personal care, animal nutrition, and others. They have various product forms, which are capsules, tablets, softgels, powder, liquids, and gummies. The various distribution channels through which nutraceuticals are available are: specialty stores; supermarkets and hypermarkets; convenience stores; drug stores and pharmacies; online retail stores; and other distribution channels. The nutraceuticals research report is one of a series of new reports from The Business Research Company that provides nutraceuticals statistics, including nutraceuticals industry global market size, regional shares, competitors with nutraceuticals share, detailed nutraceuticals segments, market trends and opportunities, and any further data you may need to thrive in the nutraceuticals industry. This nutraceuticals research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global nutraceuticals market size grew from $372.27 billion in 2022 to $409.12 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The nutraceuticals market size is expected to grow to $596.81 billion in 2027 at a CAGR of 9.9%. The rise in the geriatric population is significantly contributing to the growth of the nutraceutical market. Nutraceuticals are products that can be taken by an individual along with a normal daily diet to get additional nutrients to promote good health and immunity. After a certain age, especially after 65 years or above, an individual requires additional nutrients to build immunity to fight against a number of diseases like diabetes, cholesterol, blood pressure, and other age-related issues. Nutraceuticals are used as daily supplements to meet the daily requirements of nutrients. For instance, in 2020, according to the United Nations, there were approximately 727 million people aged 65 and above worldwide, and that number is expected to reach approximately 1.5 billion by 2050. Therefore, the rise in the geriatric population is driving the growth of the nutraceutical market. New product development is the key trend being followed by the companies operating in the nutraceutical market. This is due to the presence of a large number of nutraceutical companies operating in the market and their desire to extend their growth in new areas to be a leader in the market. For instance, in December 2021, Nestlé Health Science, a Switzerland-based nutrition company, developed a product named Reducose with the use of the plant-based ingredient mulberry leaf extract powder as an artificial sweetener for prediabetic patients, which helps to maintain a normal blood glucose response. The Reducose by Nestle Health Science has been proven to have a positive effect on postprandial blood glucose levels by reducing them by 40%. It can be added to meals or drinks to sweeten them without altering the original taste and texture of the food. In November 2021, ADM, a US-based multinational food processing company, acquired Deerland Probiotics & Enzymes for an undisclosed amount. Through this acquisition, ADM aims to enhance its prebiotics, probiotics, and postbiotics supplement portfolio in customised food and beverage products to meet growing demands from consumers across the globe for a wide variety of dietary supplements, functional foods, beverages, and pet nutrition that enhance health and wellbeing. Deerland Probiotics & Enzymes, Inc. is a US-based dietary supplement manufacturing company. The company specialises in the development of science-backed solutions that benefit health using probiotic, prebiotic, and enzyme technology. Major players in the nutraceuticals market are Cargill Incorporated., Abbott, ADM, BASF SE, Nestle, PepsiCo, General Mills, DuPont, DSM, Herbalife International of America Inc., Kellogg Co., Amway Corp., Innophos, W. R. Grace & Co.-Conn., and Bactolac Pharmaceutical Inc. North America was the largest region in the nutraceutical market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nutraceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the United Kingdom, and the United States are among the countries covered in the Nutraceuticals Market market report. The nutraceuticals market consists of sales of dietary supplements, functional food, medicinal food, and farmaceuticals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global nutraceuticals market is segmented - 1) By Type: Vitamins and Minerals, Probiotics, Proteins and Peptides, Omega Fatty Acids, Other Types 2) By Source: Plant, Animal, Microbial 3) By Application: Functional Food, Functional Beverages, Dietary Supplements, Personal Care, Animal Nutrition, Other Applications 4) By Product Forms: Capsules, Tablets, Softgels, Powder, Liquid, Gummies 5) By Distribution Channel: Specialty Stores, Supermarkets/Hypermarkets, Convenience Stores, Drug Stores/Pharmacies, Online Retail Stores, Other Distribution Channels

Biologics are drugs made from living cells using highly complex technology, while biosimilars are created to function similarly to biologics but are not identical to biologics. Oral biologics and biosimilar market comprise biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS, and other serious conditions and are used to treat chronic diseases such as diabetes, arthritis, and cancer. The main therapy types of oral biologics and biosimilar lymphocytes are modulators, interleukin inhibitors, and tumor necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that stop interleukins from working. The various diseases include asthma, Crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others that are treated by molecular types such as vaccines, proteins and peptides, monoclonal antibodies, and other therapies. These are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The oral biologics and biosimilars market research report is one of a series of new reports from The Business Research Company that provides oral biologics and biosimilars market statistics, including oral biologics and biosimilars industry global market size, regional shares, competitors with a oral biologics and biosimilars market share, detailed oral biologics and biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics and biosimilars industry. This oral biologics and biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oral biologics and biosimilars market size will grow from $5.37 billion in 2022 to $6.47 billion in 2023 at a compound annual growth rate (CAGR) of 20.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral biologics and biosimilars market size is expected to grow from $13.68 billion in 2027 at a CAGR of 20.6%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to propel the growth of the oral biologics and biosimilar market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases. Biologics stimulate the immune system's attack on cancer cells, aiding the body's natural defenses in getting rid of the disease-causing cells. According to a United Nations article, a US-based intergovernmental organization, by 2030, chronic diseases are predicted to account for 70% of all fatalities worldwide. It is anticipated that chronic disease will account for nearly 60% of all deaths worldwide. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the biologics and biosimilar market. Stringent regulations imposed on the approval of biosimilar are anticipated to hinder the growth of oral biologics and the biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as interchangeable drugs for biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics, out of the total 17 approved biosimilars only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar markets. The creation of new insulin biosimilar is a key trend gaining popularity in the oral biologics and biosimilar market. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin to capture the market share. For instance,In November 2021, Biocon, an India-based biopharmaceutical company launched inter-changeable biosimilar insulin. These products help to control high blood sugar in pediatric patients with type 1 diabetes and adults with type 2 diabetes and are available in a vial and prefilled pen presentations. These are interchangeable for the reference brand, Lantus (insulin glargine), allowing for substitution at the pharmacy counter. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit. Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, and Emisphere Technologies. North America was the largest region in the oral biologics and biosimilar drugs market in 2022. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oral biologics & biosimilar drugs market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oral biologics and biosimilar market consist of sales of receptor modulators, biological agents, and biosimilar lymphocytes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global oral biologics and biosimilars market is segmented - 1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, and Tumor Necrosis Factor-Alpha Inhibitors 2) By Disease: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Other Diseases 3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, and Other Molecule Types 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Peptide antibiotics refer to antibiotics made up of peptides the physical rupture of cell membranes underpins the antibacterial activity. The peptide antibiotics are used to permeate bacterial membranes, collect within bacteria, and then interfere with bacterial functioning. The main types of peptide antibiotics are ribosomal synthesized peptide antibiotics and non-ribosomal synthesized peptide antibiotics. The ribosomal synthesized peptide antibiotics destroy or modify the drug, change the drug target, decrease or raise drug uptake, and substitute a different metabolic step as the medication's target. Ribosomal synthesized peptide antibiotics refer to antimicrobial peptides generated by ribosomes and produced by practically all species, from bacteria to plants and animals. The various drugs under peptide antibiotics are daptomycin, dalbavancin, telavancin, and other drugs used to treat several diseases such as skin infection, HABP/VABP, blood stream infection, and other diseases. The peptide antibiotics are used and distributed through hospitals, homecare, specialty clinics, and other distribution channels. The peptide antibiotics market research report is one of a series of new reports from The Business Research Company that provides peptide antibiotics market statistics, including peptide antibiotics industry global market size, regional shares, competitors with a peptide antibiotics market share, detailed peptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide antibiotics industry. This peptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global peptide antibiotics market size grew from $4.23 billion in 2022 to $4.58 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The peptide antibiotics market size is expected to grow to $6.22 billion in 2027 at a CAGR of 7.9%. The increase in the prevalence of various infectious diseases is expected to propel the growth of the peptide antibiotics market. Infectious diseases are illnesses caused by harmful micro-organisms such as bacteria, fungi, parasites, and others. The major reasons for the rise in infectious diseases are rapid urbanization, climate change, increasing risk of disease emergence, and others, which have increased the demand for peptide antibiotics. Peptide antibiotics physically rupture the cell membranes and underpins the antibacterial activity. For instance, in July 2022, according to the Australian Institute of Health and Welfare, an organization that provides data and statistics about Australia's welfare and health, the cases of notifiable infectious diseases in Australia grew from 2.89 million cases in 2020 to 7.02 million cases in 2021. It shows a significant growth in the total number of cases of infectious diseases. Therefore, the increase in the incidence of infectious is driving the growth of the peptide antibiotics market. The strategic partnership is a key trend gaining popularity in the peptide antibiotics market. Major companies operating in the peptide antibiotics market are entering into partnerships to expand their market and leverage each others resources. For intsance, in January 2022, Berkeley Lights, a US-based digital cell biology company, partnered with Aanika Biosciences. In this partnership, Aanika will leverage Berkeley Lights' high-throughput, functional screening service to swiftly find and refine functional antimicrobial peptides (AMPs) capable of eliminating dangerous bacteria, particularly those that cause foodborne disease outbreaks. Furthermore, the Beacon Optofluidic Platform will be used to identify peptides that are harmful to bacteria in order to develop a novel antibacterial tag, which will then be used in their bacterial spore-based barcoding technology to secure the food supply chain. Aanika Biosciences is a US-based biotechnology company. An increase in incidence of chronic diseases is expected to drive the peptide antibiotics market. Chronic diseases are illnesses that last a year or longer, demand ongoing medical attention, and limit daily activities. Chronic diseases are on the rise as a result of increased tobacco use, poor nutrition, physical inactivity, excessive alcohol consumption, and other factors. Peptide antibiotics are used to treat chronic diseases by administering the drug in the target area. For instance, in July 2021, the National Council on Aging, Inc., a US-based charitable organization, reported that over 85% of elderly people have at least one chronic illness, and health care spending rose to $3.8 trillion annually in the US. Also, according to a research report published by American Action Forum in September 2020, chronic disease prevalence and costs are rising in the United States. They are expected to keep rising as the disease prevalence among children and young adults rises. Chronic disease is a serious healthcare problem since the rising cost of chronic disease in the United States totals $3.7 trillion annually, around 19.6% of the country's gross domestic product. Therefore, the increasing prevalence of chronic conditions is fueling the growth of the peptide antibiotics market. Major players in the peptide antibiotics market are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Theravance Biopharma, Pacgen Life Science Corporation, Kasten, Savara Pharmaceuticals, Merck KGaA, Madam Therapeutics, Allergan PLC., Dr. Reddy’s Laboratories Ltd., Sanofi, Fresenius Kabi AG, Novo Holdings A/S and Teva Pharmaceutical Industries Ltd. North America was the largest region in the peptide antibiotics market in 2022. The regions covered in the peptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the peptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The peptide antibiotics market consists of sales of oral, intravenous, intramuscular and topical peptide antibiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global peptide antibiotics market is segmented - 1) By Type: Ribosomal Synthesized Peptide Antibiotics, Non-rRibosomal Synthesized Peptide Antibiotics 2) By Drugs: Daptomycin, Dalbavancin, Telavancin, Other Drugs 3) By Disease Outlook: Skin Infection, HABP/VABP, Blood Stream Infection, Other Diseases 4) By Distribution Channel: Hospitals, Homecare, Specialty Clinics, Other Distribution Channels

Dermatitis refer to the inhibitors that treat skin inflammation, which is characterised by itchy rashes on swollen and reddish skin, in the outer layer of the body. It is a general term that describes a common skin irritation. The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones. The different routes of administration include topical, oral, and injectable and are used in cancer, blood disorders, chronic diseases, and infectious diseases. It is distributed through various channels such as hospitals, retail pharmacies, drug stores, and online or mail pharmacies. The dermatitis market research report is one of a series of new reports from The Business Research Company that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global dermatitis market size will grow from $6.46 billion in 2022 to $6.89 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global dermatitis market size is expected to grow to $8.57 billion in 2027 at a CAGR of 5.6%. Growth in the atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. The prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent. The strict government regulations are one of the restraints for the dermatitis drug market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). To find the efficacy and efficiency of the drug, it has to be tried on every type of patient. The effects of certain drugs in adults are quite different than in children, as a reasonable result of the clinical trial cannot be used for the production of drugs that will be served to the children. This hinders the research and requires more effort in clearing regulations set by FDA. For example, as the patient population is largely children, the FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation complies with the Children’s Health Act of 2000 which requires all children subjected to clinical trials to be given additional protection. The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolios and improve their market presence. Companies are also strategically making M&As to reduce competition and increase the scalability of their businesses. For instance, in January 2020, Eli Lilly and Company, a US-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of human drugs, acquired Dermira, Inc. for an amount of $1.1 billion. Through this acquisition, Lebrikizumab, an innovative, experimental monoclonal antibody, has been added to the immunology pipeline and marketed dermatology medicines in the product portfolio of Eli Lilly for the treatment of moderate-to-severe atopic dermatitis in patients 12 years of age and older. Dermira, Inc. is a US-based biopharmaceutical company pioneering in the discovery and development of novel therapies for dermatology patients. The dermatitis drugs market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) which carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products to ensure the safety, quality, and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly, CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes make the drugs more effective and safe, thereby having a positive impact on the dermatitis drugs market. Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan PLC. (Republic of Ireland) and Bristol-Myers Squibb. North America was the largest region in the dermatitis market in 2022. Middle East is expected to be the fastest-growing region in the global dermatitis market during the forecast period. The regions covered in the global dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies 3) By Route Of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases

Blood culture tests refer to blood tests used to detect and identify disease-causing microorganisms in the bloodstream. A blood culture test checks for infections caused by microorganisms like bacteria, yeast, and other foreign invaders in a blood sample. The main method of blood culture tests are conventional/manual methods and automated methods. The conventional or manual method of blood culture test is used for detection of invaders like bacteria, yeast, and other microorganisms from a blood specimen. Manual testing is performed by testers who use and test the result in a manual maaner. The blood culture product are consumables, instruments and software and services that uses technology such as culture-based technology, molecular technologies, microarrays, PCR (polymerase chain reaction); PNA-FISH (peptide nucleic acid – fluroscent in situ hybridization) and proteomics technology that are applied in bacteremia, fungemia and mycobacterial detection, used by hospital laboratories, reference laboratories, academic research laboratories, and other laboratories. The blood culture tests market research report is one of a series of new reports from The Business Research Company that provides blood culture tests market statistics, including blood culture tests industry global market size, regional shares, competitors with a blood culture tests market share, detailed blood culture tests market segments, market trends and opportunities, and any further data you may need to thrive in the blood culture tests industry. This blood culture tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood culture tests market size grew from $5.51 billion in 2022 to $6.24 billion in 2023 at a compound annual growth rate (CAGR) of 13.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The blood culture tests market size is expected to grow to $9.31 billion in 2027 at a CAGR of 10.5%. The increase in incidence of infectious diseases is expected to propel the growth of the blood culture test market. Infectious diseases are illnesses caused by pathogens, including viruses, bacteria, fungi, and parasites. These diseases have dangerous microorganisms or pathogens that enter an individual's body from the outside or from an infected person. These infectious diseases, such as COVID-19, tuberculosis, flu, measles, HIV, strep throat, and so on, have the potential to cause momentary pain, significant tissue damage, or even death. The World Health Organization ranks infectious diseases as the second biggest cause of death globally. These increases in the incidence of infectious diseases have led to an increase in the demand for blood culture tests to assist in determining whether a patient has bacteremia/septicemia, a potentially fatal condition, or not. For instance, in 2022, the World Health Organization, stated that approximately 6.4 million people died from COVID-19. Furthermore, due to tuberculosis (TB), a total of 1.5 million people died in 2020 worldwide. Therefore, the increasing incidence of infectious diseases is driving the growth of the blood culture test market. The technological innovation is a key trend gaining popularity in the blood culture tests market. Innovation and globalization are creating new prospects for the pharmaceutical, biologics, nutraceuticals, and medical device industries. The desire to bring new products to market safely, quickly, and affordably necessitates producers and manufacturers to build world-class blood culture testing to demonstrate compliance with ever-expanding requirements. These technological innovations reduce costs through accurate and independent safety and performance assurance. For instance, In May 2022, Labcorp, a US-based testing laboratories company, launched Labcorp OnDemandTM at-home collection kit that measures hemoglobin A1c (HbA1c) from a small blood sample. This OnDemand Diabetes test kit employs dried blood technology to provide an overview of the body's average blood sugar levels over time. Through this kit, users can monitor their health status regularly from the comfort of their homes with a prick of the finger and a few drops of blood. In October 2021, Dr. Lal Path Labs, an India-based diagnostic and related healthcare tests provider, acquired Suburban Diagnostics for an 1150 cr ($14.39 million). This acquisition gives LPL access to 44 laboratories and diagnostics centers (one of which is CAP-accredited and five are NABL accredited) and 150+ collection centers. Suburban Diagnostics is an India-based diagnostics center and pathology lab. Major players in the blood culture tests market are Becton, Dickinson and Company, bioMérieux SA, Thermo Fisher Scientific Inc., Luminex Corporation, Danaher Corporation, Bruker Corporation, Roche Diagnostics, T2 Biosystems Inc., OpGen Inc., F. Hoffmann-La Roche AG, HiMedia Laboratories Pvt. Ltd., Axiom Laboratories, Abbott Laboratories, Ibis Biosciences Inc., and Magnolia Medical Technologies. North America was the largest region in the blood culture tests market in 2022. The regions covered in the blood culture tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood culture tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The blood culture tests include revenues earned by entities by micro sampling technology and blood chemistry analyzer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood culture tests market is segmented - 1) By Method: Conventional/Manual Methods, Automated Methods 2) By Product: Consumables, Instruments, Software and Services 3) By Technology: Culture-Based Technology, Molecular Technologies, Microarrays, PCR (Polymerase Chain Reaction), PNA-FiSH (Peptide Nucleic Acid – Fluroscent in Situ Hybridization), Proteomics Technology 4) By Application: Bacteremia, Fungemia, Mycobacterial Detection 5) By End User: Hospital Laboratories, Reference Laboratories, Academic Research Laboratories, Other Laboratories

Veterinary antibiotics refer to a class of animal medications that are used to treat infectious disease in animals by killing microorganisms such as bacteria and parasites by inhibiting the growth of their cell walls to fight infections and diseases in animals caused by bacteria and improve the animals' health conditions. The main product types of veterinary antibiotics include anti-parasitic, anti-bacterial, non-steroidal anti-inflammatory drugs, and other products. Non-steroidal anti-inflammatory drugs (NSAIDs) act as a bridge between the production and activity of prostaglandins (enzymes) implicated in inflammation. Approved veterinary NSAIDs are used in companion animal care to reduce the pain and swelling linked with osteoarthritis in dogs and horses. The administration of veterinary antibiotics includes premixes, injections, oral powders, oral solutions, and other administrations used on farm animals and companion animals. The veterinary antibiotics research report is one of a series of new reports from The Business Research Company that provides veterinary antibiotics statistics, including veterinary antibiotics industry global market size, regional shares, competitors with veterinary antibiotics share, detailed veterinary antibiotics segments, market trends and opportunities, and any further data you may need to thrive in the veterinary antibiotics industry. The veterinary antibiotics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global veterinary antibiotics market size will grow from $1.86 billion in 2022 to $2.02 billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global veterinary antibiotics market size is expected to grow to $2.7 billion in 2027 at a CAGR of 7.5%. An increase in the number of zoonotic diseases is driving the veterinary antibiotics market. Zoonotic diseases are infectious diseases caused by microscopic organisms, infections, and parasites that spread between animals and humans. Two of the most common zoonotic pathogens, salmonella and campylobacter, are present in the intestines of these animals. Zoonotic diseases are also a potential threat to humans as they get transferred through the food chain. A study conducted by the FoodNet (Centers for Disease Control and Prevention, USA) found that 24,484 foodborne illnesses, 5,677 hospitalizations, and 122 deaths are caused by zoonotic diseases. In addition, the highest incidences per 100,000 people in the USA are caused by infectious diseases such as campylobacter, salmonella, and shigella. Therefore, there is a need to diagnose these diseases in animals at an early stage, which is a major driver of the veterinary antibiotics market. The rising threat of antibiotic resistance is a major restraint for the veterinary antibiotics market. Antibiotic resistance in animals refers to the ability of a microbe to withstand the impact of an antibiotic that once successfully treated infections caused by the same type of microbe. This can be a result of using antibiotics more than the prescribed limit. In this regard, the European Union (EU) has approved various restrictions on veterinary antibiotics, including a ban on antibiotics for animals and prohibiting the usage of antimicrobials in food, which is restricting the growth of the veterinary antibiotics market. Increasing collaboration between companies is an emerging trend in the veterinary antibiotics market. Collaboration offers companies the opportunity to combine technologies and a wide range, more diversified products to work with, and it also improves the quality of the antibiotics and the speed at which they are produced. Therefore, companies in the veterinary antibiotics market are focusing on collaborations. For instance, in September 2022, GlobalVetLink, a US-based provider of software services and informatics solutions in the field of animals, collaborated with Veterinary Innovative Partners to install GlobalVetLink Compliance Assistant, a thorough SaaS platform developed to simplify animal health. The veterinary antibiotics prescription drugs market is regulated by Section 503(f) of the Food, Drug, and Cosmetic Act of FDA. According to this law, the veterinary antibiotic drug labels are mandated to include a caution statement that states that these drugs can only be used with the permission of a licenced veterinarian. The sale and use of antibiotic prescription drugs without a prescription is usually reported to the FDA and strict action is taken based on it. Hence, regulations such as these would regulate veterinary antibiotic manufacturers and sellers. Major players in the veterinary antibiotics market are Bayer AG, Boehringer Ingelheim GmbH, CevaSanteAnimale, Eli Lilly Company, ElanCo., Merck & Co., Sanofi, Virbac, Zoetis, and Crystal Pharma. North America was the largest region in the veterinary antibiotics market in 2022. Asia-Pacific was the second-largest region in the global veterinary antibiotics market. The regions covered in the global veterinary antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary antibiotics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The veterinary antibiotics market consists of sales of antivirals, antiprotozoals, antifungals, aminoglycosides, beta-lactams, fluoroquinolones, glycopeptides, and lipopeptides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary antibiotics market is segmented - 1) By Product: Anti-Parasitic, Anti-Bacterial, Non-Steroidal Anti-Inflammatory Drug, Other Products 2) By End User: Farm Animals, Companion Animals 3) By Administration: Premixes, Injections, Oral Powders, Oral Solutions, Other Administration

Nutritional feed additives various types of products used in animal nutrition to improve the nutritional content and quality of feed, or to improve the health and performance of animals. They help improve the nutritional content and quality of feed, resulting in higher productivity and disease prevention. The main additive types of nutritional feed additives are antibiotics, vitamins, antioxidants, amino acids, enzymes, mycotoxin detoxifiers, prebiotics, probiotics, flavours and sweeteners, pigments, binders, and minerals. Antibiotics are medications that aid in the treatment of bacterial illnesses. They accomplish this by either killing the bacteria or preventing them from replicating or reproducing. The nutritional feed additives are available in various forms, such as dry, liquid, and other forms that are used on ruminants, poultry, swine, and aquatic livestock. The additives are distributed through direct, indirect channels; hypermarkets and supermarkets; specialty stores, and online retail channels. The nutritional feed additives research report is one of a series of new reports from The Business Research Company that provides nutritional feed additives statistics, including nutritional feed additives industry global market size, regional shares, competitors with nutritional feed additives share, detailed nutritional feed additives segments, market trends and opportunities, and any further data you may need to thrive in the nutritional feed additives industry. This nutritional feed additives research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nutritional feed additives market size will grow from $3.89 billion in 2022 to $4.19 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global nutritional feed additives market size is expected to grow to $5.41 billion in 2027 at a CAGR of 6.6%. The rise in consumption of meat products is one of the driving factors for the nutrition feed additives market. Due to high meat consumption, the concern for high-quality meat is also increasing. Thus, to deliver high-quality meat, add-on nutrition feed additives are fed to the animals so that they have good digestion to build on more muscle and weight. This increases the yield and productivity and, hence, the demand for nutritional feed additives. Currently, meat and poultry consumption in the US is more than 100 billion pounds every year. The stringent regulations act as one of the major restraining factors for the nutrition feed additives market. There are many mandatory documents, required to be approved before approving the nutritional feed, which delays the approval process. Therefore, the product launch and expansion of companies in new regional markets will be delayed. For instance, China's AQSIQ (Administration for Quality Supervision and Inspection and Quarantine) issued 2 reports for the nutrition feed additive companies to get their products registered and approved by the concerned Chinese authorities before selling them in the Chinese market. The report also made it compulsory for all the exporters to have a licence to sell their nutrition feed additive products in the Chinese market, which delays the nutritional feed additives from reaching the stores. Feed additives manufacturers are investing in the R&D of organic feed additives as there is a growing demand for organic and natural feed products in the nutritional feed additives market. When compared to synthetic nutrition feed additives, organic feed additives have fewer side effects and also improve yield. Therefore, poultry farmers are switching to herbal nutrition feed additives. For instance, Agpulse Organics has come up with its herbal animal feed additive 'Govahnika-Biosheera', which is fed to cattle to increase milk productivity while maintaining the health of cattle and quality of milk. In September 2020, Adisseo acquired Framelco G for an undisclosed amount. With this acquisition, the company will enhance the growth of specialties to become the world leader in the field of specialty feed ingredients in animal nutrition. Framelco G is a family-owned multinational company that develops and manufactures feed additives and drinking water solutions for livestock production. Major players in the nutritional feed additives market are BASF SE, Cargill, Archer Daniels Midland Company, Evonik Industries AG, Nutreco N.V., Kemin Industries Inc., Adisseo, Alltech, Phibro Animal Health Corporation, and DowDuPont. North America was the largest region in the nutritional feed additives market in 2022. Asia-Pacific was the second-largest region in the global nutritional feed additives market. The regions covered in the global nutritional feed additives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nutritional feed additives market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The nutritional feed additives market consists of sales of digestibility enhancers, coccidiostats and histomonostats, antimicrobials, and growth hormones. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global nutritional feed additives market is segmented - 1) By Distribution Channel: Direct, Indirect, Hypermarket/Supermarket, Specialty Stores, Online Retail 2) By Livestock: Ruminants, Poultry, Swine, Aquatic 3) By Additive Type: Antibiotics, Vitamins, Antioxidants, Amino Acids, Enzymes, Mycotoxin Detoxifiers, Prebiotics, Probiotics, Flavors And Sweeteners, Pigments, Binders, Minerals 4) By Form: Dry, Liquid, Other Forms